BIOGEN INC. (BIIB) FY2025 Annual Balance Sheet

Balance Sheet

As of 2025-12-31

Swipe to see the full flow
BIOGEN INC. (BIIB) FY2025 Annual Balance SheetBalance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.Current liabilities$3.35 BCurrent assets$8.97 BLiabilities$11.18 BAssets$29.44 BNon-current liabilities$7.83 BEquity$18.26 BNon-current assets$20.47 BGross equity(calculated)$21.42 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsInventoryAccounts receivable, net of allowance for doubtful accounts of $3.0 and $2.2, respectivelyOther current assetsCurrent portion of marketable securitiesDue from anti-CD20 therapeutic programsIntangible assets, netGoodwillProperty, plant and equipment, netInvestments and other assetsMarketable securitiesDeferred tax assetOperating lease assetsAccrued expense and otherAccounts payableTaxes payableNotes payableOther long-term liabilitiesDeferred tax liabilityLong-term operating lease liabilitiesRetained earningsAdditional paid-in capitalCommon stock, par value $0.0005 per shareCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury stock, at cost; 23.8 million and 23.8 million shares, respectivelyAccumulated other comprehensive income (loss)Cash and cash equivalentsCash and cash equivalents$3.01 BCurrent liabilitiesCurrent liabilities$3.35 BAccrued expense and otherAccrued expense and other$2.80 BCurrent assetsCurrent assets$8.97 BInventoryInventory$2.17 BAccounts payableAccounts payable$432.00 MLiabilitiesLiabilities$11.18 BAccounts receivable, net of allowance for doubtful accounts of $3.0 and $2.2, respectivelyAccounts receivable, net$1.34 BTaxes payableTaxes payable$114.80 MOther current assetsOther current assets$1.12 BAssetsAssets$29.44 BNon-current liabilitiesNon-current liabilities$7.83 BNotes payableNotes payable$6.29 BCurrent portion of marketable securitiesCurrent portion of marketable securities$807.20 MOther long-term liabilitiesOther long-term liabilities$748.50 MDue from anti-CD20 therapeutic programsDue from anti-CD20 therapeutic programs$524.60 MDeferred tax liabilityDeferred tax liability$507.60 MEquityEquity$18.26 BLong-term operating lease liabilitiesLong-term operating lease liabilities$290.40 MIntangible assets, netIntangible assets, net$9.18 BNon-current assetsNon-current assets$20.47 BGross equity (calculated)Gross equity(calculated)$21.42 BGoodwillGoodwill$6.49 BRetained earningsRetained earnings$20.55 BProperty, plant and equipment, netProperty, plant and equipment, net$3.06 BInvestments and other assetsInvestments and other assets$750.60 MMarketable securitiesMarketable securities$431.90 MAdditional paid-in capitalAdditional paid-in capital$863.10 MDeferred tax assetDeferred tax asset$292.50 MCommon stock, par value $0.0005 per shareCommon stock, par value $0.0005 per share$100.00 KOperating lease assetsOperating lease assets$265.40 MTreasury stock, at cost; 23.8 million and 23.8 million shares, respectivelyTreasury stock−$2.98 BAccumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)−$182.00 M
Chart details

BIOGEN INC. (BIIB) FY2025 Annual Balance Sheet

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

Assets
29,439,500,000 US dollars
Current assets
8,974,100,000 US dollars
Non-current assets
20,465,400,000 US dollars
Liabilities
11,182,700,000 US dollars
Current liabilities
3,349,400,000 US dollars
Non-current liabilities
7,833,300,000 US dollars
Equity
18,256,800,000 US dollars
Cash and cash equivalents
3,008,500,000 US dollars
Inventory
2,168,100,000 US dollars
Accounts receivable, net of allowance for doubtful accounts of $3.0 and $2.2, respectively
1,342,400,000 US dollars
Other current assets
1,123,300,000 US dollars
Current portion of marketable securities
807,200,000 US dollars
Due from anti-CD20 therapeutic programs
524,600,000 US dollars
Intangible assets, net
9,178,500,000 US dollars
Goodwill
6,491,100,000 US dollars
Property, plant and equipment, net
3,055,400,000 US dollars
Investments and other assets
750,600,000 US dollars
Marketable securities
431,900,000 US dollars
Deferred tax asset
292,500,000 US dollars
Operating lease assets
265,400,000 US dollars
Accrued expense and other
2,802,600,000 US dollars
Accounts payable
432,000,000 US dollars
Taxes payable
114,800,000 US dollars
Current portion of notes payable
0 US dollars
Notes payable
6,286,800,000 US dollars
Other long-term liabilities
748,500,000 US dollars
Deferred tax liability
507,600,000 US dollars
Long-term operating lease liabilities
290,400,000 US dollars
Retained earnings
20,552,700,000 US dollars
Additional paid-in capital
863,100,000 US dollars
Common stock, par value $0.0005 per share
100,000 US dollars
Preferred stock, par value $0.001 per share
0 US dollars
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively
negative 2,977,100,000 US dollars
Accumulated other comprehensive income (loss)
negative 182,000,000 US dollars
Gross equity (calculated)
21,415,900,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
BIOGEN INC. (BIIB) FY2025 Annual Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!